Michael Hunt, CFO at Reneuron Plc (LON:RENE), spoke to Proactive ahead of new data being presented at the 26th Annual Congress of the European Society of Gene and Cell Therapy (ESGCT) relating to its CTX stem cell platform.
The platform is currently being taken through the clinic as a possible treatment for stroke patients, with long-term data suggesting it can improvement motor function and reduce levels of disability.
The new data suggests CTX could be reprogrammed and used to produce new non-donor-specific cell lines, including NK and T-Cells – the cells that can be modified to attack cancer cells.